A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

Inclusion Criteria Concurrent Medication: Allowed: * Antiretrovirals provided dose has been stable for at least 6 weeks prior to study entry. Patients must have: * HIV seropositivity. * Mild to moderate cognitive impairment (problems with short term memory, concentration, and feeling slowed down). * No active opportunistic CNS infection. * Ability to give informed consent. Prior Medication: Allowed: * Prior antiretrovirals provided dose has been stable for at least the past 6 weeks. * Prior thioctic acid or deprenyl. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Severe premorbid psychiatric illness including schizophrenia and major depression that would interfere with study compliance. * CNS neoplasms. * Any other clinically significant condition or laboratory abnormality that would preclude participation on study. * Current participation in other drug studies. Concurrent Medication: Excluded: * Chemotherapy for malignancy. Patients with the following prior conditions are excluded: * History of chronic neurological disorders such as serious head injury, documented stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other neurodegenerative processes such as Huntington's disease. * Prior participation in this study. * History of adverse reaction/allergy to thioctic acid or deprenyl. Prior Medication: Excluded: * Other investigational drugs within 30 days prior to study entry.